期刊文献+

盐酸奈法唑酮片治疗抑郁症的临床试验 被引量:2

A randomized, double blind and positive control clinical trial of nefazodone for the treatment of depression
下载PDF
导出
摘要 目的:评价国产盐酸奈法唑酮片治疗抑郁症的有效性和安全性。方法:随机、双盲、双模拟、阳性药平行对照、剂量可调整研究。48例抑郁症患者随机分为奈法唑酮组24例与氟西汀组24例,分别口服盐酸奈法唑酮片200~500 mg·d-1或氟西汀10~40 mg·d-1,疗程42 d。结果:治疗14 d起两组汉密尔顿抑郁量表(HAMD)评分较基线均显菩减少(P<0.01);奈法唑酮组与氟西汀组有效率分别为85.7%与83.3%,差异无显著性(P>0.05)。奈法唑酮常见的不良反应为恶心呕吐、头昏、头痛,发生率与氟西汀相当。结论:盐酸奈法唑酮治疗抑郁症安全、有效。 Objective:To evaluate the efficacy and safety of nefazodone made in China in the treatment of depression. Methods: A randomized, double blind positive control clinical trial enrolled forth-eight patients with depression, who were randomized 1 : 1 to administer nefazodone 300 mg or fluoxetine 20 mg daily for 42 days. The efficacy of both treatment groups was evaluated based on HAMD, CGI and clinical general impression scale pre- and post-treatment. Results:Compared to the baseline scores, patients (P〈0. experienced significant improvements in the Hamilton Depression Scale at the end of the therapy 05). The efficacy rate in both treatment groups was 85.7% and 83.3% , respectively; the P value showed no significant difference (P 〉 0.05). Both therapies demonstrated common adverse events including nausea, dizziness, dry mouth, and poor appetite ( P 〉 0. 05). Conclusion : made in China offers an effective and safe option in the treatment of depression.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第6期464-466,共3页 Chinese Journal of New Drugs
关键词 奈法唑酮 氟西汀 抑郁症 汉密尔顿抑郁量表(HAMD) nefazodone fluoxetine depression drug evaluation
  • 相关文献

参考文献4

  • 1DAVIS R, WHITTINGTON R, BRYSON HM. Nefazodone, a review of its pharmacology and clinical efficacy in the management of major depression [ J ]. Drugs, 1997,53 (4) : 608 - 636.
  • 2PIRRAGLIA PA, STAFFORD RS, SINGER DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care[ J]. J Clin Psychiatry,2003,5(4) :153 - 157.
  • 3PRESKRON SH. Comparison of tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, setraline and venlafaxine [ J ]. J Clin Psychiatry, 1995,56 ( Suppl 6 ) : S12 - S21.
  • 4BALDWIN DS. Sexual dysfunction associated with antidepressant drugs [J]. Expert Opin Drug Saf, 2004,3(5) :457-470.

同被引文献17

  • 1李一云,季建林.文拉法辛与米氮平治疗抑郁症的临床比较分析[J].上海精神医学,2003,15(6):358-360. 被引量:23
  • 2白燕,王继才,许秀峰.盐酸奈法唑酮片治疗抑郁症的Ⅱ期临床研究[J].昆明医学院学报,2004,25(4):87-91. 被引量:2
  • 3肖融,吴薇莉,张伟.惊恐障碍的病因学特征[J].中国临床康复,2005,9(48):111-113. 被引量:9
  • 4翟金国,赵靖平.新型抗抑郁药治疗焦虑谱系障碍研究进展[J].中国药学杂志,2007,42(14):1041-1045. 被引量:17
  • 5Nanber R, Rush A J, Tsase ME, et al. The effects of psychotherapy, nefazodone,and their combination on subjective assessment of disturbed sleep in chronic depression [J].Sleep,2003,26(2): 130-136.
  • 6Eison AS,Eison MS,Torrente JR, et al. Nefazodone: Preclinical pharmacology of a new antidepepressant[J].Psychopharmacol Bull,1989, 26(3):311-315.
  • 7Shukla UA, Marathe PH, Pittman RA. Pharmacokinetics,absolute bioavailabiliy and disposition of 14C-nefazodone in the dog[J]. Drug Metab Dispos,1993,21(3):502-507.
  • 8Benfield P, Heel RC,Lewis SP.FLuoxetine a review of its pharmacod- ynamic and pharmacokinetic proper-ties and therapeutic efficacy in depressive illness[J].Drugs,1986,32(6):481-508.
  • 9Van Harten J.Clinical pharmacokinetics of selective serotonin reuptake irdaibitors[J]. Clin Phamacokinet, 1993,24(3):203-220.
  • 10Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and phamacodinetic properties and therapeutic efficacyindepressive illness[J].Drugs, 1986,32(4):313-334.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部